Photo by nci from unsplash
Ibrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor associated with dramatic improvements in outcomes of various B-cell hematologic malignancies and is now standard therapy. However, Ibrutinib is associated with… Click to show full abstract
Ibrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor associated with dramatic improvements in outcomes of various B-cell hematologic malignancies and is now standard therapy. However, Ibrutinib is associated with a >4-fold increased risk of incident atrial arrhythmias. Recently, an alarming
Keywords:
managed ibrutinib;
patients managed;
arrhythmias patients;
ventricular arrhythmias;
ibrutinib cancer;
arrhythmias
Journal Title: Journal of the American College of Cardiology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!